Skip to main content
Fig. 11 | Clinical Epigenetics

Fig. 11

From: Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells

Fig. 11

MAKV-8 combined with imatinib displays a differential toxicity in healthy cells compared to CML cells. CML and healthy cells were treated with the indicated concentrations of imatinib alone or in combination with MAKV-8. (a) Healthy cell models were treated for 48h. Cell viability was assessed based on the Trypan Blue exclusion method for PBMCs, by flow cytometry after Annexin V staining for platelets, and nuclear morphology was examined in RPMI-1788 cells. SAHA was used as a reference HDACi. (b) CML cells were pre-treated with MAKV-8 for 8h and then grown in semisolid methylcellulose medium in the presence of imatinib. After 10-day incubations, cell colony-forming capacity was scored after MTT addition. Representative pictures (left panel) and corresponding quantifications (right panel) from three independent experiments are provided

Back to article page